First ever MASH drug primed for big impact in USA

Research suggests there will likely be strong uptake for the first USA-approved therapy for metabolic dysfunction-associated steatohepatitis (MASH).

Madrigal Pharmaceuticals (Nasdaq: MDGL) recently scored a US Food and Drug Administration (FDA)  nod for Rezdiffra (resmetirom) as a treatment for MASH, alongside diet and exercise.

As the first prescription medicine for a large treatment opportunity, Rezdiffra has the potential to generate revenues in excess of $3.5 billion annually before the end of the decade, according to Leerink Partners.